• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Brady Huggett

Brady Huggett

Articles

ARTICLES

SuperGen Receives Approval For Supergeneric Mitozytrex

Nov. 18, 2002
By Brady Huggett

Confirmatory Phase III Prestara Protocol Submitted By Genelabs

Nov. 18, 2002
By Brady Huggett
Genelabs Technologies Inc. has laid the groundwork for a confirmatory Phase III trial of its lupus drug, Prestara, and said it expects to begin the trial before the end of the year. (BioWorld Today)
Read More

Confirmatory Phase III Prestara Protocol Submitted By Genelabs

Nov. 18, 2002
By Brady Huggett
Genelabs Technologies Inc. has laid the groundwork for a confirmatory Phase III trial of its lupus drug, Prestara, and said it expects to begin the trial before the end of the year. (BioWorld Today)
Read More

SuperGen Receives Approval For Supergeneric Mitozytrex

Nov. 18, 2002
By Brady Huggett

Celgene Buying Anthrogenesis For $45M, Expanding Portfolio

Nov. 15, 2002
By Brady Huggett
Celgene Corp. is shelling out $45 million in stock and options to acquire a subsidiary - a placental stem cell recovery company called Anthrogenesis Corp. (BioWorld Today)
Read More

Celgene Buying Anthrogenesis For $45M, Expanding Portfolio

Nov. 15, 2002
By Brady Huggett
Celgene Corp. is shelling out $45 million in stock and options to acquire a subsidiary - a placental stem cell recovery company called Anthrogenesis Corp. (BioWorld Today)
Read More

Ligand Changes Avinza Deal With Elan, Misses On Earnings

Nov. 14, 2002
By Brady Huggett
Ligand Pharmaceuticals Inc. is restructuring its Avinza license deal with Elan Corp. plc, eliminating Elan's co-promotion rights in North America and dropping Elan's royalty rate. But to do so, Ligand will pick up $135 million in debt for a product that is not generating revenue as strongly as management had predicted, a scenario that has investors questioning the future.
Read More

Ligand Changes Avinza Deal With Elan, Misses On Earnings

Nov. 14, 2002
By Brady Huggett
Ligand Pharmaceuticals Inc. is restructuring its Avinza license deal with Elan Corp. plc, eliminating Elan's co-promotion rights in North America and dropping Elan's royalty rate. But to do so, Ligand will pick up $135 million in debt for a product that is not generating revenue as strongly as management had predicted, a scenario that has investors questioning the future.
Read More

Incyte Buying Maxia For $28.3M; Plans Staff, Expense Reductions

Nov. 13, 2002
By Brady Huggett
Incyte Genomics Inc., known for its databases and research solutions, is acquiring Maxia Pharmaceuticals Inc. and its pipeline of early stage drugs for an amount that could reach $42.3 million. Also Tuesday, the company released its third-quarter earnings and said it was reducing staff by 37 percent and planning to seriously reduce expenses. (BioWorld Today)
Read More

Incyte Buying Maxia For $28.3M; Plans Staff, Expense Reductions

Nov. 13, 2002
By Brady Huggett
Incyte Genomics Inc., known for its databases and research solutions, is acquiring Maxia Pharmaceuticals Inc. and its pipeline of early stage drugs for an amount that could reach $42.3 million. Also Tuesday, the company released its third-quarter earnings and said it was reducing staff by 37 percent and planning to seriously reduce expenses. (BioWorld Today)
Read More
View All Articles by Brady Huggett

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe